Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 39
Filtrar
1.
J Am Acad Dermatol ; 88(4): 848-855, 2023 04.
Artigo em Inglês | MEDLINE | ID: mdl-36368376

RESUMO

BACKGROUND: Primary melanoma management relies on tumor extirpation and staging sentinel lymph node biopsy (SLNB) in eligible patients. This study compares SLNB utilization in patients undergoing wide local excision (WLE) or Mohs micrographic surgery (MMS). METHODS: American Joint Committee on Cancer seventh edition ≥ patients with T1b melanoma undergoing WLE or MMS in the Surveillance, Epidemiology, and End Results program were included. Propensity score matching was performed to compare patients who underwent MMS or WLE. Kaplan-Meier analysis and Fine-Gray cumulative incidence functions were used for overall and melanoma-specific survival. RESULTS: Eight hundred twenty-five MMS cases and 38,760 WLE cases were identified. SLNB was performed in 32.61% of MMS patients and 61.77% of WLE patients with positive rates of 12.5% and 14.82%, respectively. Multiple logistic regression of factors associated with SLNB utilization revealed that WLE, male gender, younger age, extremity location, and nodular and rare melanoma subtypes were significantly associated with increased odds of receiving SLNB whereas head and neck location and lentigo maligna melanoma subtype were significantly less likely to receive SLNB. LIMITATIONS: Potential selection bias from a retrospective data set. CONCLUSION: Patients receiving WLE for ≥ T1b melanoma are more likely to receive a SLNB than patients undergoing MMS.


Assuntos
Melanoma , Linfonodo Sentinela , Neoplasias Cutâneas , Humanos , Masculino , Biópsia de Linfonodo Sentinela/métodos , Neoplasias Cutâneas/patologia , Cirurgia de Mohs/métodos , Estudos Retrospectivos , Modelos Logísticos , Melanoma/patologia , Análise de Sobrevida , Excisão de Linfonodo , Linfonodo Sentinela/patologia
2.
J Am Acad Dermatol ; 87(4): 807-814, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-35787410

RESUMO

BACKGROUND: The effect of treatment delays on melanoma outcomes remains unclear. OBJECTIVE: To assess the impact of surgical treatment delays on melanoma-specific mortality (MSM) and overall mortality (OM). METHODS: Patients with stage I to III cutaneous melanoma were identified through the Surveillance, Epidemiology, and End Results database (N = 108,689). Included cases had time from diagnosis to definitive surgery and follow-up time. Cox proportional hazards and Fine-Gray competing risks analyses were used to assess the impact of treatment delays on mortality. RESULTS: Across all stages, treatment delays of 3 to 5 months were associated with worse MSM and any delay beyond 1 month was associated with worse OM. In a subgroup analysis of patients with stage I disease, delays of 3 to 5 months were associated with worse MSM and any delay beyond 1 month was associated with worse OM. In patients with stage II disease, worse MSM was found with delays of 6+ months and worse OM was seen with delays of 3 to 5 months. No significant effect of treatment delays was noted in stage III disease. LIMITATIONS: The Surveillance, Epidemiology, and End Results database does not collect comprehensive data on adjuvant treatments, disease recurrence, or treatment failure. CONCLUSION: Timely treatment of melanoma may be associated with improved OM and MSM.


Assuntos
Melanoma , Neoplasias Cutâneas , Humanos , Melanoma/diagnóstico , Melanoma/epidemiologia , Melanoma/cirurgia , Estadiamento de Neoplasias , Medição de Risco , Programa de SEER , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/cirurgia , Melanoma Maligno Cutâneo
3.
J Am Acad Dermatol ; 82(5): 1195-1204, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-31887322

RESUMO

BACKGROUND: Brigham and Women's Hospital stage T2a squamous cell carcinomas, demonstrating a single high-risk feature, have a low risk of metastasis and death but an increased risk of local recurrence. Little evidence exists for the best treatment modality and associated outcomes in T2a squamous cell carcinoma. OBJECTIVE: We aimed to compare outcomes for T2a squamous cell carcinoma treated by Mohs micrographic surgery compared with wide local excision with permanent sections. METHODS: Retrospective review of an institutional review board-approved single-institution registry of T2a squamous cell carcinoma. RESULTS: Three hundred sixty-six primary T2a tumors were identified, including 240 squamous cell carcinomas (65.6%) treated with Mohs micrographic surgery and 126 (34.4%) treated with wide local excision. A total of 32.5% of patients were immunosuppressed and mean oncologic follow-up was 2.8 years. Local recurrence was significantly more likely after wide local excision (4.0%) than after Mohs micrographic surgery (1.2%) (P = .03). Multiple logistic regression demonstrated immunocompromised state (odds ratio [OR] 5.1; 95% confidence interval [CI] 1.1-23.3; P = .03) and wide local excision (OR 4.8; 95% CI 1.1-21.6; P = .04) associated with local recurrence; and wide local excision (OR 7.8; 95% CI 2.4-25.4; P < .001), high-risk head and neck location (OR 8.3; 95% CI 1.8-38.7; P = .004), and poor histologic differentiation (OR 4.7; 95% CI 1.4-15.4; P = .03) associated with poor outcomes (overall recurrence or disease-specific death). CONCLUSION: Mohs micrographic surgery provides improved outcomes in Brigham and Women's Hospital T2a squamous cell carcinoma.


Assuntos
Carcinoma de Células Escamosas/cirurgia , Cirurgia de Mohs , Recidiva Local de Neoplasia/epidemiologia , Neoplasias Cutâneas/cirurgia , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Escamosas/epidemiologia , Carcinoma de Células Escamosas/patologia , Feminino , Seguimentos , Humanos , Masculino , Margens de Excisão , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/prevenção & controle , Estadiamento de Neoplasias , Estudos Retrospectivos , Fatores de Risco , Pele/patologia , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/patologia , Resultado do Tratamento
4.
J Am Acad Dermatol ; 82(3): 700-708, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31756403

RESUMO

BACKGROUND: Opioid overprescribing is a major contributor to the opioid crisis. The lack of procedure-specific guidelines contributes to the vast differences in prescribing practices. OBJECTIVE: To create opioid-prescribing consensus guidelines for common dermatologic procedures. METHODS: We used a 4-step modified Delphi method to conduct a systematic discussion among a panel of dermatologists in the fields of general dermatology, dermatologic surgery, and cosmetics/phlebology to develop opioid prescribing guidelines for some of the most common dermatologic procedural scenarios. Guidelines were developed for opioid-naive patients undergoing routine procedures. Opioid tablets were defined as oxycodone 5-mg oral equivalents. RESULTS: Postoperative pain after most uncomplicated procedures (76%) can be adequately managed with acetaminophen and/or ibuprofen. Group consensus identified no specific dermatologic scenario that routinely requires more than 15 oxycodone 5-mg oral equivalents to manage postoperative pain. Group consensus found that 23% of the procedural scenarios routinely require 1 to 10 opioid tablets, and only 1 routinely requires 1 to 15 opioid tablets. LIMITATIONS: These recommendations are based on expert consensus in lieu of quality evidence-based outcomes research. These recommendations must be individualized to accommodate patients' comorbidities. CONCLUSIONS: Procedure-specific opioid prescribing guidelines may serve as a foundation to produce effective and responsible postoperative pain management strategies after dermatologic interventions.


Assuntos
Analgésicos Opioides/uso terapêutico , Dermatologia , Prescrições de Medicamentos/normas , Dor Pós-Operatória/tratamento farmacológico , Padrões de Prática Médica , Procedimentos Cirúrgicos Dermatológicos , Feminino , Humanos , Masculino , Guias de Prática Clínica como Assunto
5.
Dermatol Surg ; 46(9): 1141-1147, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-31702595

RESUMO

BACKGROUND: Limited information exists on the demographics, tumor characteristics, and treatment in primary cutaneous mucinous carcinoma (PCMC). OBJECTIVE: The authors sought to describe prognostic factors, incidence rates, and the subsequent primary malignancy (SPM) risk in patients with PCMC. METHODS: Primary cutaneous mucinous carcinoma cases in the National Cancer Institute's Surveillance, Epidemiology, and End Results data (1972-2013) were analyzed to provide demographic, cancer-related, and treatment information and to calculate incidence and mortality. Patients were stratified by stage (local, regional, distant disease) for comparison. The risk of developing an SPM was calculated. RESULTS: Four hundred eleven PCMC cases were identified. The age-adjusted incidence was 0.04 cases per 100,000-person years. Blacks were disproportionately affected by PCMC (0.048; 95% confidence interval, 0.034-0.065; p < .001). Approximately 67.4% of patients had local disease, 10.5% had regional disease, and 5.8% had distant disease. Primary cutaneous mucinous carcinoma-specific mortality was independent of sex, age, race, primary site, histologic tumor grade, tumor size, tumor stage, or treatment. The overall frequency of developing a second primary malignancy was not increased in patients with PCMC. CONCLUSION: Although PCMC occurs with equally in both sexes, it may be more common in African Americans than previously recognized. Although eyelid PCMC may have a higher rate of distant metastasis, all patients need close follow-up.


Assuntos
Adenocarcinoma Mucinoso/mortalidade , Neoplasias Palpebrais/mortalidade , Programa de SEER/estatística & dados numéricos , Neoplasias Cutâneas/mortalidade , Adenocarcinoma Mucinoso/patologia , Adenocarcinoma Mucinoso/terapia , Adolescente , Adulto , Negro ou Afro-Americano/estatística & dados numéricos , Idoso , Idoso de 80 Anos ou mais , Neoplasias Palpebrais/patologia , Neoplasias Palpebrais/terapia , Pálpebras/patologia , Feminino , Humanos , Incidência , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Gradação de Tumores , Estadiamento de Neoplasias , Prognóstico , Pele/patologia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/terapia , Resultado do Tratamento , Estados Unidos/epidemiologia , Adulto Jovem
6.
Dermatol Surg ; 46(8): 1021-1029, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-31929340

RESUMO

BACKGROUND: The Affordable Care Act (ACA) and the appropriate use criteria (AUC) for Mohs micrographic surgery (MMS) had the potential to increase utilization rates of MMS for indicated skin cancers, but it is unknown whether this has occurred. OBJECTIVE: To determine whether rates of MMS utilization for head and neck melanoma in situ (MIS) and rare cutaneous tumors (RCTs) increased after the implementation of the ACA and AUC publication. MATERIALS AND METHODS: Retrospective review using data from the SEER database. Melanoma in situ and RCT tumor cases from before and after the ACA and AUC publication were compared. RESULTS: Twenty-four thousand six hundred seventy-eight cases were analyzed. Mohs micrographic surgery utilization for MIS decreased from 13.9% before the ACA to 12.3% after the ACA (odds ratio 0.87; p = .012). There was no significant change in MMS utilization for MIS after publication of the AUC. There was also no significant change in MMS utilization for treatment of RCT after the ACA or AUC publication. Stratification of patients into age groups younger or older than 65 years did not change utilization rates. CONCLUSION: Rates of MMS for treatment of MIS and RCT have not increased since the advent of the ACA or AUC. This finding highlights the need for continued efforts to improve access to MMS and to increase education of its utility in treating skin cancer.


Assuntos
Neoplasias de Cabeça e Pescoço/cirurgia , Melanoma/cirurgia , Cirurgia de Mohs/estatística & dados numéricos , Cirurgia de Mohs/tendências , Neoplasias Cutâneas/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Renda , Masculino , Melanoma/patologia , Pessoa de Meia-Idade , Patient Protection and Affordable Care Act , Áreas de Pobreza , Guias de Prática Clínica como Assunto , Doenças Raras/cirurgia , Programa de SEER , Neoplasias Cutâneas/patologia , Estados Unidos , Adulto Jovem
7.
Dermatol Surg ; 46(11): 1375-1381, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32106119

RESUMO

BACKGROUND: Squamous cell carcinoma (SCC) is the most common malignant tumor of the nail unit. No guidelines currently exist regarding the role of imaging in this specific location. OBJECTIVE: To investigate the utility of routine imaging in SCC of the nail apparatus. METHODS: A multi-institutional retrospective review of patients treated for nail unit SCC was performed. Data were collected on patient characteristics, tumor qualities, treatment, and radiographic imaging. A change in treatment was defined as more aggressive treatment (amputation) rather than local excision or Mohs micrographic surgery (MMS). RESULTS: One hundred seven patients with nail unit SCC were identified. Approximately 44/107 (41.1%) of patients were imaged and 63/107 (58.9%) were not. Mohs micrographic surgery was the most common primary treatment (66.4%). Mohs micrographic surgery was more commonly performed in nonimaged patients, and amputation was more commonly performed in imaged patients (p < .001). Bony changes were identified in 13/44 (29.5%) of imaged patients. In 8/44 (18.2%), imaging findings caused a change in treatment. In 99/107 (92.5%) of the cohort, imaging was either not performed or did not change management. CONCLUSION: In select cases, imaging may help guide patient management. Sufficient evidence does not yet exist to support routine imaging for patients with nail unit SCC.


Assuntos
Carcinoma de Células Escamosas/diagnóstico , Doenças da Unha/diagnóstico , Unhas/diagnóstico por imagem , Neoplasias Cutâneas/diagnóstico , Adulto , Idoso , Amputação Cirúrgica/estatística & dados numéricos , Carcinoma de Células Escamosas/patologia , Carcinoma de Células Escamosas/cirurgia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Cirurgia de Mohs/estatística & dados numéricos , Doenças da Unha/patologia , Doenças da Unha/cirurgia , Unhas/patologia , Unhas/cirurgia , Radiografia , Estudos Retrospectivos , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/cirurgia
8.
Dermatol Surg ; 46(10): 1279-1285, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-31929338

RESUMO

BACKGROUND: Bilobed transposition flaps are versatile random pattern flaps used in nasal and extranasal reconstruction as they preserve free margins, access distal tissue reservoirs, and reliably repair dynamic defects. OBJECTIVE: We highlight the utility of extranasal bilobed flaps to encourage surgeons to consider these flaps for Mohs micrographic surgery defects. METHODS: A two-institution retrospective chart review of patients reconstructed using an extranasal bilobed flap after Mohs micrographic surgery was performed. A validated scar scale was applied to postoperative photographs. Statistical analyses of the patient and surgery characteristics including patient co-morbidities, anatomic distribution, flap dimensions, and postprocedural events, including revisions, were conducted. RESULTS: Forty-eight patients were identified. Site-specific flap dimensions were obtained with the cheek/lower eyelid requiring greater tissue mobilization with a higher final to primary defect ratio when compared with other sites. Postoperative events (complications, erythema, flap fullness, dehiscence, infection, etc.) were minimal. No major complications were noted. Nine cases of flap fullness or swelling were identified. Neither flap fullness nor dehiscence compromised flap integrity or cosmetic outcome. Independent flap cosmetic outcome review was good using a validated photographic scar scale. CONCLUSION: Bilobed transposition flaps are versatile repairs for extranasal reconstruction with a favorable safety and outcome profile.


Assuntos
Cicatriz/diagnóstico , Complicações Pós-Operatórias/diagnóstico , Neoplasias Cutâneas/cirurgia , Retalhos Cirúrgicos/transplante , Ferida Cirúrgica/cirurgia , Idoso , Idoso de 80 Anos ou mais , Cicatriz/etiologia , Cicatriz/prevenção & controle , Estética , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Cirurgia de Mohs/efeitos adversos , Fotografação , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/prevenção & controle , Estudos Retrospectivos , Índice de Gravidade de Doença , Pele/diagnóstico por imagem , Ferida Cirúrgica/etiologia , Resultado do Tratamento
10.
Dermatol Surg ; 44(7): 911-917, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29578881

RESUMO

BACKGROUND: As a rare cutaneous malignancy, epidemiologic and outcomes data for aggressive digital papillary adenocarcinoma (ADPA) are limited and no treatment guidelines exist. OBJECTIVE: To provide a population-based study of ADPA incidence and outcomes with a subgroup comparison of patients with localized versus regional disease. METHODS: Data from 18 registries within the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program were examined for patients with ADPA (1995-2013) to provide demographic- and cancer-related information, and to calculate race- and age-specific rate ratios, incidence, and mortality. Patients were stratified by the stage for further comparison. RESULTS: Ninety-four cases of ADPA were identified. Overall, ADPA incidence was 0.08 per 1,000,000 person-years, 4 times higher in males than in females (0.13 vs 0.03, p < .001), and most common in Caucasians. Regional disease spread occurred in 22.3% of patients and disease-specific mortality in 2.1% of patients. Patients with regional versus localized disease at diagnosis did not differ significantly in sex, age, race, primary site, tumor size, or mortality. CONCLUSION: Aggressive digital papillary adenocarcinoma is a rare malignancy with increasing incidence. Regional disease spread is not infrequent, but mortality is rare. Identification of patients best suited for additional diagnostic procedures or more extensive surgical resection remains challenging.


Assuntos
Adenocarcinoma Papilar/epidemiologia , Neoplasias das Glândulas Sudoríparas/epidemiologia , Adenocarcinoma Papilar/patologia , Adenocarcinoma Papilar/terapia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Demografia , Glândulas Écrinas , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Sistema de Registros , Estudos Retrospectivos , Programa de SEER , Taxa de Sobrevida , Neoplasias das Glândulas Sudoríparas/patologia , Neoplasias das Glândulas Sudoríparas/terapia , Resultado do Tratamento , Estados Unidos/epidemiologia , Adulto Jovem
13.
14.
Facial Plast Surg ; 33(1): 97-101, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28226377

RESUMO

Previous scar scales have focused on verbal descriptions. A nonverbal visual assessment tool would provide a simple way for patients and physicians to quantify scar appearance. The authors sought to use a validated visual assessment tool for linear surgical scars to assess linear scars on the face and to determine whether patients and surgeons rate scars similarly. A total of 143 patients with linear facial scars resulting from repair of Mohs micrographic surgery defects used the visual assessment tool to rate their surgical scar. Six physicians used the tool to rate a subset of the patients' scar photographs. The scar ratings for patients and physicians were compared. Among the scars rated by both the patients and physicians (n = 79), patients had a significantly lower mean (i.e., more favorable) rating compared with the physicians. This was a single-center study including only Caucasian patients. The visual assessment tool to rate linear surgical scars provided a simple method for both patients and physicians to assess the overall appearance of postsurgical scars. Difference in the scar ranking between patients and physicians indicate the importance of incorporating both patient and physician point of view when assessing scars.


Assuntos
Cicatriz , Face , Pacientes , Médicos , Cicatriz/etiologia , Estética , Humanos , Cirurgia de Mohs/efeitos adversos , Variações Dependentes do Observador , Percepção Visual
17.
J Am Acad Dermatol ; 72(2): 340-4, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25458017

RESUMO

BACKGROUND: Shared medical appointments (SMAs) allow patients with similar diagnoses to be simultaneously educated and cared for by 1 provider. SMAs appear well suited for Mohs micrographic surgery because all patients receive similar information about skin cancer pathophysiology, prognosis, prevention, treatment, reconstructive options, and wound care. OBJECTIVE: We sought to create a SMA for the preoperative consultation visit of Mohs micrographic surgery and to evaluate patient satisfaction with this model. METHODS: A pilot SMA was implemented. Patient satisfaction was assessed via a 13-question survey over a 6-month period. RESULTS: In all, 149 patients were seen in our SMAs. The survey response rate was 65.8%. Respondents answered Likert scale questions with a mean value of 4.29 ± 0.09 (on a 1-5 scale, where 5 is the best). Patients found the SMA model useful (84.7%) and would attend another SMA in the future (80.6%). LIMITATIONS: Limitations include the sample size of the study, relatively homogenous patient population, possible response bias, and a potential selection bias (as all participants in the SMA chose this type of appointment rather than a conventional one). CONCLUSIONS: SMA can be successfully used for the Mohs preoperative consultation visit with high patient satisfaction.


Assuntos
Agendamento de Consultas , Processos Grupais , Cirurgia de Mohs/métodos , Educação de Pacientes como Assunto/organização & administração , Satisfação do Paciente , Cuidados Pré-Operatórios/métodos , Encaminhamento e Consulta/organização & administração , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Basocelular/cirurgia , Carcinoma de Células Escamosas/cirurgia , Feminino , Humanos , Disseminação de Informação , Masculino , Pessoa de Meia-Idade , Modelos Organizacionais , Visita a Consultório Médico , Avaliação de Resultados em Cuidados de Saúde , Educação de Pacientes como Assunto/métodos , Projetos Piloto , Vigilância da População , Padrões de Prática Médica/organização & administração , Neoplasias Cutâneas/cirurgia
19.
Dermatol Surg ; 41(12): 1411-8, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26551772

RESUMO

BACKGROUND: Hypertrophic lichen planus is a chronic variant of lichen planus with controversial malignant association. OBJECTIVE: To describe and analyze the relationship of squamous cell carcinoma (SCC) and hypertrophic lichen planus. MATERIALS AND METHODS: A retrospective chart review of patients with hypertrophic lichen planus and SCC was performed at the authors' institution. Thereafter, scientific databases were searched for articles reporting cases of SCC arising in hypertrophic lichen planus. Patient demographics, immune status, lichen planus features, and SCC data points were extracted for each patient and evaluated. RESULTS: Thirty-eight cases of SCC in hypertrophic lichen planus occurred in 16 women, average age: 61.4, and 22 men, average age: 51.3, after a lag time of 88 days to 40 years. Squamous cell carcinoma was uniformly located on the lower extremity. Men had larger SCC than women (p = .027) and a significantly longer lag time to SCC development (p = .002). Long lag time was associated with a smaller SCC size (p = .032). CONCLUSION: In the past, hypertrophic lichen planus and SCC have been considered isolated diseases. Based on an increasing number of cases, the association between hypertrophic lichen planus and keratinocyte malignancies warrants surveillance.


Assuntos
Carcinoma de Células Escamosas/patologia , Líquen Plano/patologia , Neoplasias Cutâneas/patologia , Idoso , Carcinoma de Células Escamosas/cirurgia , Transformação Celular Neoplásica , Feminino , Humanos , Hipertrofia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Neoplasias Cutâneas/cirurgia , Fatores de Tempo
20.
Contact Dermatitis ; 72(2): 65-74, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25345884

RESUMO

Lymphomatoid contact dermatitis is a pseudolymphoma with clinical and histological features of allergic contact dermatitis and cutaneous T cell lymphoma. Incorrect diagnosis may lead to unnecessary testing, unnecessary treatment, or patient harm. The objective of this study is to present a case to demonstrate the diagnostic challenge and overlap between allergic contact dermatitis and cutaneous T cell lymphoma in a patient with lymphomatoid contact dermatitis caused by methylchoroisothiazolinone/methylisothiazolinone and paraben mix, and to review the existing literature in order to summarize the demographics, clinical features, allergens and treatments reported for lymphomatoid contact dermatitis. A search of major scientific databases was conducted for English-language articles reporting cases of lymphomatoid contact dermatitis or additional synonymous search headings. Nineteen articles with a total of 23 patients were analysed. Lymphomatoid contact dermatitis was more common in men, with an average age of 58.5 years. Fourteen unique allergens were identified and confirmed by patch testing. However, no single test or study was diagnostic of lymphomatoid contact dermatitis. Allergen avoidance was the most useful management tool, but selected patients required topical or systemic immunosuppression. In conclusion, without specific diagnostic features, evaluation for lymphomatoid contact dermatitis should include a thorough history and examination, patch testing, and biopsy with immunohistochemistry and clonality studies.


Assuntos
Dermatite Alérgica de Contato/diagnóstico , Dermatite Alérgica de Contato/imunologia , Pseudolinfoma/diagnóstico , Pseudolinfoma/imunologia , Linfócitos T , Biópsia , Dermatite Alérgica de Contato/etiologia , Diagnóstico Diferencial , Humanos , Imuno-Histoquímica , Linfoma de Células T/diagnóstico , Masculino , Pessoa de Meia-Idade , Testes do Emplastro , Neoplasias Cutâneas/diagnóstico , Tiazóis/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa